Use access key #2 to skip to page content.
$1.00 0.07 (7.53%)
10/13/2008 3:58 PM

Curis, Inc. (CRIS)

CAPS Rating:
**

A drug discovery and development company that is seeking to leverage its innovative biological signaling pathway drug technologies to create new medicines primarily in the field of cancer.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

CRIS doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks

Total Members

20 Outperforms
3 Underperforms
 

All-Stars

9 Outperforms
3 Underperforms
 

Wall Street

1 Outperforms
0 Underperforms
 

Members bullish on CRIS are also bullish on:

Members bearish on CRIS are also bearish on:

Ticker Tags

Micro Cap (4824), Biotechnology (295)
Suggest a tag

Curis, Inc. At A Glance

Current Price: $1.00
Last Trade Time: 10/13/2008 3:58 PM
Open: $0.95
Previous Close: $0.93
Daily Range: $0.95 - $1.01
52-Week Range: $0.86 - $1.94
Volume: 89,363
Market Cap: $58.99M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

CRIS VS S&P 500 (SPY)

CRIS 12 month chart vs. S&P

News & Discussion Boards

Top Bull Pitch

Recs

2

Curis, Inc. (CRIS)

Avatar darkflame (98.51) Submitted: 5/14/07 9:21 AM

Losing 30 points on this one, why did I buy it ? I don't know... Ok, let's be honest, because a friend likes this company. Slowly he is getting bold and as he last hope he invests in this company. Shall this company be successfull he will drive a sports car and have beautfull brilliant hair, otherwi...More

Replies: 1 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 5  

Show Pitch Replies

Recs

0

 (CRIS)

Avatar usubanas (97.67) Submitted: 8/20/08 4:06 PM : Outperform Start Price: $1.89 CRIS Score: -18.06

VERY promising phase I data; 2 or 3 phase II trials beginning this year... getting in (in real life) early on this one but totally worth the risk... at $100M market cap, i predict a couple years from now it will be my second best winner ever (after IMGN).

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (CRIS)

Avatar zzlangerhans (99.10) Submitted: 8/06/08 5:56 PM : Underperform Start Price: $1.69 CRIS Score: 11.11

Curis snuck over the market cap minimum just long enough for me to tattoo them with a red thumb. Why this early stage cancer drug developer made it into the big leagues, in the current pessimistic market, is a mystery to me. Only one long-shot cancer product is in phase II and this trial isn't expected to be completed until 2011. As more phase I candidates are developed and entered into trials, the current low burn rate will explode and quickly erode the 30M in cash reserves. A comparable biotech is Ziopharm, which recently dropped down to the 30M market cap range.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (CRIS)

Avatar ID10TS (98.88) Submitted: 7/26/08 12:00 AM : Underperform Start Price: $1.66 CRIS Score: 11.43

Sales are down 2.3% over the last 5 years. Profits are negative. Income is down more then 10% of sales over the last 12months. I don't see a turn around any time soon.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (CRIS)

Avatar Rolfsted (< 20) Submitted: 7/16/08 1:26 PM : Outperform Start Price: $1.80 CRIS Score: -17.50

Cramer says biotech is hot

Report this Post Replies: 0 | Reply | Permalink

Recs

2

 (CRIS)

Avatar darkflame (98.51) Submitted: 5/14/07 9:21 AM : Outperform Start Price: $2.21 CRIS Score: -15.36

Losing 30 points on this one, why did I buy it ? I don't know... Ok, let's be honest, because a friend likes this company. Slowly he is getting bold and as he last hope he invests in this company. Shall this company be successfull he will drive a sports car and have beautfull brilliant hair, otherwise no money nor hair.

But...trying to figure out a logical reason for CAPsing this stock, well, insiders own something of it and during 2006 bought a bit more, but really just a bit.

What is this company achieving ?

From 2004 to 2006 it tripled the revenue and decreased the cost of that revenue and has managed to narrow it's loss like a good biotech company would do.

Price/Book value is 2.15. The question is if that book value is worth anything for an investor, but we are optimist today aren't we ?

Entreprise Value / Revenue is 2.65. Not bad...

What does this company need to be worth anything for you or for me ? Quick answer, keep increasing the revenue for about the same rate.

Keep this company in mind.

Report this Post Replies: 1 | Reply | Permalink

Results 1 - 5 of 5  

Wall Street

Results 1 - 1 of 1  

picks per page. CHANGE Expand All Pitches

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackEveillard 94.20 09/30/07 Outperform NS $0.98+2.04%-41.05%+43.09 Toggle the visibility of 60-Second Pitch and replies

Results 1 - 1 of 1  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners